Yeon-Mi Hwang

Yeon-Mi Hwang

Auto-generated profile, based on publicly available information

Yeon-Mi Hwang

Department of Medicine, Stanford University, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2026 in Nature Health
Verified
Journal Article
Open access
PDF file
YHYeon-Mi Hwang
Yeon-Mi Hwang
MNMadelena Y. Ng
Madelena Y. Ng
MPMalvika Pillai
Malvika Pillai
MSMichelle P. Sahai
Michelle P. Sahai
THTina Hernandez-Boussard
Tina Hernandez-Boussard
Artificial intelligence (AI) has the potential to improve healthcare delivery, but uneven adoption and implementation can reinforce existing care gaps and inefficiencies. We analysed data from 3,560 US hospitals using the 2023 American Hospital Association (AHA) Annual Survey, the 2023–2024 AHA Information Technology Supplement, community-level socioeconomic indicators, and the 2023–2025 Centers for Medicare & Medicaid Services hospital quality metrics to examine where AI is implemented, what factors are associated with implementation and the patterns of early AI adoption across geographical regions. Here we found that hospital AI implementation is considerably clustered, with hotspots and coldspots of adoption. Regions with greater healthcare access needs were less likely to have hospitals with AI-based predictive models. Geographically weighted regression showed that factors associated with predictive AI implementation vary by region, suggesting that adoption patterns reflect diverse local contexts and institutional characteristics. These findings provide a baseline snapshot of early AI deployment patterns in US hospitals in 2023 and 2024, highlighting the uneven and context-dependent nature of implementation. Future efforts should develop standardized, detailed, model-specific AI implementation metrics and account for local contexts rather than pursuing uniform deployment strategies.

28 June 2024 in Science Advances
Verified
Journal Article
Open access
APAlison G. Paquette
Alison G. Paquette
KAKylia Ahuna
Kylia Ahuna
YHYeon Mi Hwang
Yeon Mi Hwang
JPJocelynn Pearl
Jocelynn Pearl
HLHanna Liao
Hanna Liao
NPNathan Price
Nathan Price
Gene regulation is essential to placental function and fetal development. We built a genome-scale transcriptional regulatory network (TRN) of the human placenta using digital genomic footprinting and transcriptomic data. We integrated 475 transcriptomes and 12 DNase hypersensitivity datasets from placental samples to globally and quantitatively map transcription factor (TF)–target gene interactions. In an independent dataset, the TRN model predicted target gene expression with an out-of-sample R 2 greater than 0.25 for 73% of target genes. We performed siRNA knockdowns of four TFs and achieved concordance between the predicted gene targets in our TRN and differences in expression of knockdowns with an accuracy of >0.7 for three of the four TFs. Our final model contained 113,158 interactions across 391 TFs and 7712 target genes and is publicly available. We identified 29 TFs which were significantly enriched as regulators for genes previously associated with preterm birth, and eight of these TFs were decreased in preterm placentas.

1 February 2024 in eClinicalMedicine
Verified
Journal Article
Open access
YHYeon Mi Hwang
Yeon Mi Hwang
QWQi Wei
Qi Wei
SPSamantha N. Piekos
Samantha N. Piekos
BVBhargav Vemuri
Bhargav Vemuri
SMSevda Molani
Sevda Molani
JHJennifer Hadlock
Jennifer Hadlock
Background Immune -mediated inflammatory diseases (IMIDs) are likely to complicate maternal health. However, literature on patients with IMIDs undergoing pregnancy is scarce and often overlooks the presence of comorbidities. We aimed to evaluate the impact of IMIDs on adverse pregnancy outcomes after assessing and addressing any discrepancies in the distribution of covariates associated with adverse pregnancy outcomes between patients with and without IMIDs. Methods We conducted a retrospective cohort study using data from an integrated U.S. community healthcare system that provides care across Alaska, California, Montana, Oregon, New Mexico, Texas, and Washington. We used a database containing all structured data from electronic health record (EHRs) and analyzed the cohort of pregnant people who had live births from January 1, 2013, through December 31, 2022. We investigated 12 selected IMIDs: psoriasis, inflammatory bowel disease, rheumatoid arthritis, spondyloarthritis, multiple sclerosis, systemic lupus erythematosus, psoriatic arthritis, antiphospholipid syndrome, Sjogren's syndrome, vasculitides, sarcoidosis, and systemic sclerosis. We characterized patients with IMIDs prior to pregnancy (IMIDs group) based on pregnancy/ maternal characteristics, comorbidities, and pre-pregnancy/prenatal immunomodulatory medications (IMMs) prescription patterns. We 1:1 propensity score matched the IMIDs cohort with people who had no IMID diagnoses prior to pregnancy (non-IMIDs cohort). Outcome measures were preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA), and caesarean section. Findings Our analytic cohort had 365,075 people, of which 5784 were in the IMIDs group and 359,291 were in the non-IMIDs group. The prevalence rate of pregnancy of at least 20 weeks duration in people with a previous IMID diagnosis has doubled in the past ten years. 17% of the IMIDs group had at least one prenatal IMM prescription. Depending on the type of IMM, 48%-70% of the patients taking IMMs before pregnancy continued them throughout pregnancy. Overall, patients with one or more of these 12 IMIDs had increased risk of PTB (Relative risk (RR) = 1.1 [1.0, 1.3]; p = 0.08), LBW (RR = 1.2 [1.0, 1.4]; p = 0.02), SGA (RR = 1.1 [1.0, 1.2]; p = 0.03), and caesarean section (RR = 1.1 [1.1, 1.2], p < 0.0001) compared to a matched cohort of people without IMIDs. When adjusted for comorbidities, patients with rheumatoid arthritis (PTB RR = 1.2, p = 0.5; LBW RR = 1.1, p = 0.6) and/or inflammatory bowel disease (PTB RR = 1.2, p = 0.3; LBW RR = 1.0, p = 0.8) did not have significantly increased risk for PTB and LBW. Interpretation For patients who have been pregnant for 20 weeks or greater, the association between IMIDs and adverse pregnancy outcomes depends on both the nature of the IMID and the presence of comorbidities. Because this study was limited to pregnancies resulting in live births, results must be interpreted together with other studies on early pregnancy loss and stillbirth in patient with IMIDs. Funding National Institutes of Health.

2 January 2024 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Open access
YHYeon Mi Hwang
Yeon Mi Hwang
RRRyan T. Roper
Ryan T. Roper
SPSamantha N. Piekos
Samantha N. Piekos
DEDaniel A. Enquobahrie
Daniel A. Enquobahrie
MHMary F. Hebert
Mary F. Hebert
JHJennifer Hadlock
Jennifer Hadlock
There is uncertainty around the safety of SSRIs for treating depression during pregnancy. Nevertheless, the use of SSRIs has been gradually increasing, especially during the COVID-19 pandemic period. We aimed to (1) characterize maternal depression rate and use of SSRIs in a recent 10-year period, (2) address confounding by indication, as well as socioeconomic and environmental factors, and (3) evaluate associations of the timing of SSRI exposure in pregnancy with risk for preterm birth (PTB), low birthweight (LBW), and small for gestational age (SGA) infants among women with depression before pregnancy. We conducted propensity score-adjusted regression to calculate odds ratios (ORs) of PTB, LBW, and SGA. We accounted for maternal/pregnancy characteristics, comorbidity, depression severity, time of delivery, social vulnerability, and rural residence. There were 50.3% and 40.3% increases in the prevalence rate of prenatal depression and prenatal SSRI prescription rate during the pandemic. We identified women with depression ≤180 days before pregnancy (n = 8406). Women with no SSRI order during pregnancy (n = 3760) constituted the unexposed group. The late SSRI exposure group consisted of women with an SSRI order after the first trimester (n = 3759). The early-only SSRI exposure group consisted of women with SSRI orders only in the first trimester (n = 887). The late SSRI exposure group had an increased risk of PTB of OR = 1.5 ([1.2,1.8]) and LBW of OR = 1.5 ([1.2,2.0]), relative to the unexposed group. Associations between late SSRI exposure and risk of PTB/LBW were similar among a subsample of patients who delivered during the pandemic. These findings suggest an association between PTB/LBW and SSRI exposure is dependent on exposure timing during pregnancy. Small for gestational age is not associated with SSRI exposure.

28 July 2023 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
YHYeon-Mi Hwang
Yeon-Mi Hwang
SPSamantha Piekos
Samantha Piekos
TSTanya Sorensen
Tanya Sorensen
LHLeroy Hood
Leroy Hood
JHJennifer Hadlock
Jennifer Hadlock
Background: Both COVID-19 and pregnancy are associated with hypercoagulability. Due to the increased risk for thrombosis, the United States National Institute of Health’s recommendation for prophylactic anticoagulant use for pregnant patients has expanded from patients hospitalized for severe COVID-19 manifestation to all patients hospitalized for the manifestation of COVID-19 (no guideline: before December 26, 2020; first update: December 27, 2022; second update: February 24, 2022-present). However, no study has evaluated this recommendation. Objective: The objective of this study was to characterize prophylactic anticoagulant use among hospitalized pregnant people with COVID-19 from March 20, 2020, to October 19, 2022. Methods: This was a retrospective cohort study in large US health care systems across 7 states. The cohort of interest was pregnant patients who were hospitalized with COVID-19, without previous coagulopathy or contraindication to anticoagulants (n=2767). The treatment group consisted of patients prescribed prophylactic dose anticoagulation between 2 days before and 14 days after COVID-19 treatment onset (n=191). The control group was patients with no anticoagulant exposure between 14 days before and 60 days after COVID-19 treatment onset (n=2534). We ascertained the use of prophylactic anticoagulants with attention to the updates in guidelines and emerging SARS-CoV-2 variants. We propensity score matched the treatment and control group 1:1 on the most important features contributing to the prophylactic anticoagulant administration status classification. Outcome measures included coagulopathy, bleeding, COVID-19–related complications, and maternal-fetal health outcomes. Additionally, the inpatient anticoagulant administration rate was validated in a nationwide population from Truveta, a collective of 700 hospitals across the United States. Results: The overall administration rate of prophylactic anticoagulants was 7% (191/2725). It was lowest after the second guideline update (no guideline: 27/262, 10%; first update: 145/1663, 8.72%; second update: 19/811, 2.3%; P<.001) and during the omicron-dominant period (Wild type: 45/549, 8.2%; Alpha: 18/129, 14%; Delta: 81/507, 16%; and Omicron: 47/1551, 3%; P<.001). Models developed on retrospective data showed that the variable most associated with the administration of inpatient prophylactic anticoagulant was comorbidities prior to SARS-CoV-2 infection. The patients who were administered prophylactic anticoagulant were also more likely to receive supplementary oxygen (57/191, 30% vs 9/188, 5%; P<.001). There was no statistical difference in a new diagnosis of coagulopathy, bleeding, or maternal-fetal health outcomes between those who received treatment and the matched control group. Conclusions: Most hospitalized pregnant patients with COVID-19 did not receive prophylactic anticoagulants across health care systems as recommended by guidelines. Guideline-recommended treatment was administered more frequently to patients with greater COVID-19 illness severity. Given the low rate of administration and differences between treated and untreated cohorts, efficacy could not be assessed.

26 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
YHYeon-Mi Hwang
Yeon-Mi Hwang
MNMadelena Y. Ng
Madelena Y. Ng
MSMichelle P. Sahai
Michelle P. Sahai
MPMalvika Pillai
Malvika Pillai
THTina Hernandez-Boussard
Tina Hernandez-Boussard
Hospitals are increasingly adopting artificial intelligence (AI) tools in clinical care. However, their overall impact on the health of older adults remains unclear. We assessed whether county-level hospital AI implementation was associated with elder mortality and care quality using national data from the American Hospital Association (AHA), Centers for Medicare & Medicaid Services (CMS), and CDC WONDER. Higher AI implementation was associated with lower elder deaths from all causes, circulatory and respiratory conditions, along with improvements in pneumonia and heart failure mortality, reduced hospital readmissions, and staff vaccination rates. However, we also found associations between AI implementation and increased rates of high-risk opioid prescribing and sepsis shock incidence. These findings highlight both the potential benefits and unintended consequences of AI in elder care. Given limitations in data specificity and the cross-sectional study design, future research should adopt longitudinal methods and promote more standardized reporting of AI use.